RHYTHM PHARMACEUTICALS, INC. Earnings Per Share (Basic)
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Earnings Per Share (Basic) of -$0.73 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-04
- RHYTHM PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.73.
- RHYTHM PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.83.
- RHYTHM PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2025-12-31 was -$0.73.
- RHYTHM PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.82.
- RHYTHM PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2025 was -$3.11.
- RHYTHM PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2024 was -$4.34.
- RHYTHM PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2023 was -$3.20.
- RHYTHM PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2022 was -$3.47.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.73 10-Q · filed 2026-08-04 | -$1.57 10-Q · filed 2026-08-04 | -$2.30 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$3.12 derived: net income ÷ weighted average shares · filed 2026-08-04 |
| 2026-03-31 | -$0.83 10-Q · filed 2026-05-05 | -$1.57 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$2.38 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$3.14 derived: net income ÷ weighted average shares · filed 2026-08-04 |
| 2025-12-31 | -$0.73 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$1.55 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.30 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$3.11 10-K · filed 2026-02-26 |
| 2025-09-30 | -$0.82 10-Q · filed 2025-11-04 | -$1.57 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$2.38 10-Q · filed 2025-11-04 | -$3.11 derived: net income ÷ weighted average shares · filed 2026-08-04 |
| 2025-06-30 | -$0.75 10-Q · filed 2026-08-04 | -$1.56 10-Q · filed 2026-08-04 | -$2.28 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$3.02 derived: net income ÷ weighted average shares · filed 2026-08-04 |
| 2025-03-31 | -$0.81 10-Q · filed 2026-05-05 | -$1.53 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$2.27 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$2.82 derived: net income ÷ weighted average shares · filed 2026-05-05 |
| 2024-12-31 | -$0.72 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$1.46 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.01 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$4.34 10-K · filed 2026-02-26 |
| 2024-09-30 | -$0.73 10-Q · filed 2025-11-04 | -$1.28 derived: net income ÷ weighted average shares · filed 2025-11-04 | -$3.62 10-Q · filed 2025-11-04 | -$4.33 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2024-06-30 | -$0.55 10-Q · filed 2025-08-05 | -$2.89 10-Q · filed 2025-08-05 | -$3.60 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$4.38 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2024-03-31 | -$2.35 10-Q · filed 2025-05-07 | -$3.07 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$3.84 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$4.68 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2023-12-31 | -$0.70 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$1.47 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.28 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$3.20 10-K · filed 2026-02-26 |
| 2023-09-30 | -$0.76 10-Q · filed 2024-11-06 | -$1.58 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$2.50 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$0.82 10-Q · filed 2024-08-06 | -$1.74 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | -$0.92 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$3.47 10-K · filed 2025-02-28 | |||
| 2022-09-30 | -$0.79 10-Q · filed 2023-11-08 | -$2.73 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | -$0.89 10-Q · filed 2023-08-01 | -$1.94 10-Q · filed 2023-08-01 | ||
| 2022-03-31 | -$1.05 10-Q · filed 2023-05-02 | |||
| 2021-12-31 | -$1.40 10-K · filed 2024-02-29 | |||
| 2021-09-30 | -$0.70 10-Q · filed 2022-11-08 | -$0.54 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | -$0.70 10-Q · filed 2022-08-03 | $0.17 10-Q · filed 2022-08-03 | ||
| 2021-03-31 | $0.92 10-Q · filed 2022-05-03 | |||
| 2020-12-31 | -$3.04 10-K · filed 2023-03-01 | |||
| 2020-06-30 | -$0.71 10-Q · filed 2021-08-03 | -$1.48 10-Q · filed 2021-08-03 | ||
| 2020-03-31 | -$0.78 10-Q · filed 2021-05-03 | |||
| 2019-12-31 | -$3.86 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |